Dentists, Drs. Jessica and Thomas Gibbs, Provide Teeth Tomorrow to Glen Ellyn, IL

Prettau Zirconia is the only dental implant material with a verified five-year, 100 percent success rate.

Glen Ellyn, IL (PRWEB)
December 31, 2019

Drs. Thomas and Jessica Gibbs, dentists in Glen Ellyn, IL, now offer the new, leading full arch dental implant solution, Teeth Tomorrow®. Many patients with numerous missing teeth or ill-fitting dentures consider dental implants as the ideal solution for improved aesthetics, function, and overall health. Unlike the latest trend of same-day dental implants, Teeth Tomorrow focuses on providing proper gum healing and creating strong, long-lasting dental bridges.

Unlike traditional teeth-in-a-day procedures, with Teeth Tomorrow, patients can heal overnight allowing the swelling from surgery to decrease. When they return the next day, patients are given an immediately functional dental appliance. These appliances are made in a dental lab overnight, creating a more refined dental bridge than those made in a dental office.

The final Teeth Tomorrow dental appliance is crafted from a solid block of Prettau® Zirconia, a unique, high-quality material that does not chip, crack, stain, or attract plaque. Prettau Zirconia is the only dental implant material with a verified five-year, 100 percent success rate. Custom-crafted, these zirconia bridges are made to each patient’s individual specifications, improving function as well as complementing facial aesthetics. The Teeth Tomorrow dental implant solution is now the preferred full arch treatment that Drs. Thomas and Jessica Gibbs recommend.

The dentists at Smile Glen Ellyn use the latest technology to predict the best placement for each dental implant. With their cone beam 3D CT scanner, Drs. Thomas and Jessica Gibbs measure the quantity and quality of the jawbone to get a precise analysis, within 100 microns, of where each dental implant should be placed. They complete tooth extractions when necessary and offer nitrous oxide, oral sedation, and IV sedation to help each patient feel comfortable. In addition to dental implants, the dentists at Smile Glen Ellyn also offer WaterLase® laser dentistry, Invisalign®, and custom cosmetic dentistry treatments.

Patients with severely damaged or missing teeth who are looking for a dentist in Glen Ellyn, IL can connect with Drs. Thomas and Jessica Gibbs for a Teeth Tomorrow consultation by calling 630-858-8800 or visiting http://www.smileglenellyn.com.

About the Dentists

Smile Glen Ellyn has been offering the community of Glen Ellyn, IL, comprehensive dental care for over 30 years. Drs. Thomas and Jessica Gibbs provide leading-edge care in their family-friendly office, providing a range of services from general and preventative care, to restorative and cosmetic dentistry. The team specializes in gentle dentistry through sedation options, including offering advanced IV sedation for those with extreme dental anxiety. The practice is proud to improve the oral health and aesthetics of patients’ smiles in a comforting atmosphere. To learn more about Drs. Thomas and Jessica Gibbs, their team or the services they offer, visit http://www.smileglenellyn.com or call 630-858-8800 to schedule a one-on-one consultation.

Share article on social media or email:

“We are pleased to recognize Dr. Vi Hua as a UroLift Center of Excellence for his commitment to providing consistent care to BPH patients using the UroLift System treatment,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
December 31, 2019

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Dr. Vi Hua MD Valley Urologic Associates in Goodyear, AZ has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Hua has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are pleased to recognize Dr. Vi Hua as a UroLift Center of Excellence for his commitment to providing consistent care to BPH patients using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “This achievement has helped many patients experience durable, long-term relief from the burdensome symptoms of BPH while preserving sexual function*1,2.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Spheroid

A lot of researchers do not realize the advantages that multiplex imaging provides in the context of 3D cell culture model evaluation

WHITEHOUSE STATION, N.J. (PRWEB)
December 31, 2019

At this year’s SLAS conference, Visikol will present several talks on the exhibition floor throughput the conference that will be broadly focused on 3D cell culture, advanced imaging and multiplex analysis. Specifically, the Visikol team will discuss its NASH 3D cell culture assays for assessing steatosis, inflammation and fibrosis as well as a 2D cell culture approach for characterizing immune cell synapses for use in immuno-oncology screening programs. Additionally, Visikol will discuss broadly its approaches to multiplex imaging of both intact 3D cell culture models and traditional tissue sections from whole tissues.

“Our focus as a company has always been to transform tissues into data and to mine this data for actionable insights. We find that our Clients are not terribly interested in raw data, they are interested in insights which allow them to make more informed decisions as part of their drug discovery programs,” described Visikol CEO Dr. Michael Johnson. To this end, Visikol will discuss through the talks its approaches to not only characterize the complex spatial information contained within complex three-dimensional cell culture models but also approaches for gathering multiplexed data to answer multiple research questions simultaneously.

“A lot of researchers do not realize the advantages that multiplex imaging provides in the context of 3D cell culture model evaluation wherein we can answer several individual and counter-dependent research questions at the same time. For example, we can study the penetration kinetics of immune cells into a tumor model while also understanding secondary effects such as apoptosis and if there is preferential cell death in different types of cells,” described Visikol Head of Services Dr. Erin Edwards.

Over the last few years, the field of 3D cell culture models has dramatically changed and matured and with these changes, Visikol is continually working to improve the utility of 3D cell culture models and also to maximize their effectiveness while reducing their cost to adopt. Throughout the SLAS conference, experts in imaging, image analysis and 3D cell culture models will be present at the Visikol booth. If you are interested in discussing your next project with the team, stop by the booth or check out one of the Visikol sponsored events below.

Solutions Spotlight Info:

Use of High Content Imaging to Compare 2D and 3D Cell Culture Approaches to Model Steatosis, Inflammation, and Fibrosis in the Context of NASH

Session: Solutions Spotlight

Monday January 27, 2020

2:30 PM – 2:50 PM

Multiplexed Imaging of Slides and 3D Cell Culture Models for Deep Tissue Interrogation

Session: Solutions Spotlight

Tuesday January 28, 2020

10:30 AM – 10:50 AM

Characterization of Immune Cell Synapses for Use in Immuno-Oncology Screening Programs

Session: Solutions Spotlight

Tuesday January 28, 2020

2:00 PM – 2:20 PM

Share article on social media or email:

BROWNSVILLE, Texas (PRWEB)
December 30, 2019

Help.org, a trusted online resource for individuals who struggle with addiction and their loved ones, has announced the Best Rehab Facilities in Brownsville, Texas for 2020. The informational guide recognizes the top 3 rehab facilities based on cost, treatment options, location, accompanying services and more.

According to recent studies, drug overdose is the leading cause of death among people under age 50. In Brownsville, deaths related to opioid abuse increased significantly from 2011 to 2015. Substance abuse among adolescents is also escalating in Brownsville with 55 percent of high school students reported using alcohol, 38 percent reported using marijuana, 8 percent reported using prescription drugs without a valid prescription, and 2 percent reported using heroin. With the growing need for accessible and high-quality rehab programs, Help.org has developed a unique ranking process to help connect individuals with treatment providers that meet their needs.

The Help.org research team analyzed thousands of facilities across the country and then identified the most cost-effective and highest rated programs in larger cities like Brownsville. Each facility was evaluated based on rehabilitation services, treatment approaches, cost, special programs for unique demographics and ancillary services. The website also provides information about drug use and side effects as well as educational articles. For a detailed listing of the Best Rehab Facilities in Brownsville, Texas please visit https://www.help.org/best-drug-and-alcohol-rehab-centers-in-brownsville-tx/.

2020 Best Rehab Facilities in Brownsville, Texas (in alphabetical order)

Recovery Center of Cameron County

355 W. Elizabeth Street, Suite 100

Brownsville, TX 78521

956-548-0028

Riverwalk Ranch

6960 Dick Price Road

Mansfield, TX 76063

877-863-3869

Outcomes Detox and Recovery Center

425 East Los Ebanos Boulevard

Brownsville, TX 78520

956-621-0962

ABOUT HELP.ORG

Help.org is an online resource for individuals who struggle with addiction and their loved ones. The website provides the latest research through scientifically proven methods, community recovery resources as well as information about local financial assistance. Help.org’s team of researchers, activists and writers work together with addiction counselors and other professionals to offer useful and accurate resources to help individuals seeking recovery. To learn more, visit https://www.help.org/.

Share article on social media or email:

Tonya Shackelford,RPh

“ I am extremely excited to take the lead in an established organization with so much potential to transition into the next generation of pharmacy services. With the leadership team we have in place, we will continue to expand the healthcare experience.”— Tonya Shackelford.

TAMPA, Fla. (PRWEB)
December 30, 2019

Benzer Pharmacy today announced that Tonya Shackelford has been promoted to president of the national pharmacy chain, effective January 1, 2020. With more than 80 locations in 29 states, Tonya will lead the Benzer Pharmacy team in delivering a new vision for independent pharmacies as they continue to provide exceptional healthcare in the communities they serve.

“Tonya is an accomplished leader, with a great mix of operational experience, passion for customer care, strategic planning and business management. We are fortunate to find someone that has such a perfect set of skills for this position.” — Mani Patel, Board Member.

Shackelford has 25 years of experience in retail pharmacy and has held many leadership roles. Prior to joining Benzer in 2019, she served as the Director of Clinical and Professional Services at Fred’s Inc. and District Pharmacy Supervisor at Walgreens.

Current president, Alpesh Patel, will transition to lead business development strategies at Benzer and will remain on the Board of Directors. The board appreciates the significant contributions Alpesh has made over the past 10 years in the growth of Benzer Pharmacy. His focus on new business development will help take Benzer to the next level.

Share article on social media or email:

Dr. Rastegar-Lari

I’m excited to be partnering with Smile Brands to open this state-of-the-art facility and serve the community of Leander.

IRVINE, Calif. (PRWEB)
December 30, 2019

Smile Brands Inc., one of the nation’s leading providers of business support services to dental groups in the United States, today announced the grand opening of another affiliated Castle Dental office, serving the community of Leander, TX.

Patients will enjoy convenient hours, a comfortable office and full-service care at the new Leander location. The newest Castle Dental office provides full-service general dentistry, plus specialty care services, such as orthodontics (braces), Invisalign®, oral surgery, periodontics, endodontics, and implants. Located at 1295 S Highway 183, Suite 103, in Leander, the office will be open six days a week, including evenings and select Saturdays. Castle Dental accepts most major insurance plans and offers flexible financing options so patients can afford the care they need.

To celebrate the grand opening, the new Leander dental office will offer a special $29 new patient check-up package, including an exam with an oral cancer screening and digital x-rays, and $100 off dental services over $300. Opening this new location helps Smile Brands and its affiliated dental groups achieve their mission to provide “Smiles for Everyone”® by bringing affordable dental care to local neighborhoods.

Leading the clinical team in the new Castle Dental office is Dr. Mehran Rastegar-Lari. Dr. Rastegar-Lari has advanced training in implant dentistry and Invisalign®. He has also volunteered with Dentistry from the Heart to provide dental care to those in need.

“I enjoy getting to know my patients so they can have a positive experience during their treatment,” says Dr. Rastegar-Lari. “I’m excited to be partnering with Smile Brands to open this state-of-the-art facility and serve the community of Leander.”

This new office is open on Mondays and Fridays from 8am – 5pm, Tuesdays and Wednesdays from 7am – 4pm, Thursdays from 9am – 6pm, and select Saturdays from 8am – 5pm.

Prospective patients can call the new Leander Castle Dental office at 512-690-2868 or toll-free at 1-800-TO-SMILE (1-800-867-6453). People can also visit us online to schedule an appointment at the new Leander location.

About Smile Brands Inc.

Based in Irvine California, Smile Brands Inc. is one of the largest providers of support services to dental groups in the United States. The culture-driven organization is the #1 ranked multi-location healthcare provider on Glassdoor’s 2019 Best Places to Work list. Smile Brands provides comprehensive business support services through exclusive long-term agreements with affiliate dental groups, so dentists can spend more time caring for their patients and less time on the administrative, marketing, and financial aspects of operating a dental practice. Smile Brands supports 440 Bright Now!® Dental, Monarch Dental®, Castle Dental®, A+ Dental Care, OneSmile Dental, Johnson Family Dental, P3 Dental Group, and DecisionOne Dental Partners offices in 18 states, including Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana, Maryland, Ohio, Oregon, Nevada, Pennsylvania, Tennessee, Texas, Utah, Virginia, Washington, and Wisconsin. Smile Brands is a portfolio company of Gryphon Investors, a leading middle-market private equity firm based in San Francisco, CA. For more information, visit http://www.smilebrands.com.

Share article on social media or email:

“Dr. Ian M. Stormont has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
December 30, 2019

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Dr. Ian M. Stormont MD, Grant Regional Health in Lancaster, WI, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Stormont has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“Dr. Ian M. Stormont has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit.

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Looking forward to 2020, research will involve improving the detectability of amorphous domains in solid samples via a collaboration with Purdue University’s TEM facilities.

WEST LAFAYETTE, Ind. (PRWEB)
December 26, 2019

2019 was another great year for Improved Pharma LLC, highlighted by a highly successful AAPS meeting and several internal advances in our problem-solving capabilities. At the AAPS, the Improved Pharma booth was grouped with other formulation companies and was able to establish several contacts and initial collaborations. Improved Pharma was near Hovione, experts in spray drying, and Biddle Sawyer, suppliers of some exciting new excipients. Improved Pharma presented a poster and a Rapid Fire presentation on its Synchrotron methods.

• 
  Formulation – The most interesting formulation project this year involved re-formulating a drug product to vastly increase the solubility. The work, still on-going, has already resulted in newly filed Intellectual Property for the client.
• Synchrotron X-ray problem solving and analysis – Several projects this year utilized synchrotron technology. Most projects focused on PDF work or the detection of low amounts of polymorphic contaminants, but there was also a project needing to detect low amounts of amorphous material in a highly crystalline sample. Improved Pharma continues to develop this methodology and is pushing the capabilities even further
• Analytical Testing – There is always a need for analytical testing, and Improved Pharma continues to expand their capabilities through a combination of resources at Purdue and the acquisition of key pieces of equipment
• Solving pharmaceutical problems – The most interesting projects are those requiring outside-the-box thinking. It’s not uncommon to have unexpected results during drug development, and sometimes it can be a challenge to fully understand the results, what caused them, and how they can be improved. These projects continue to be some of the most rewarding projects Improved Pharma undertakes, as it is the key to innovations, new intellectual property, and reduced time to market.
• Research – Today’s problems could be better solved by tomorrow’s solutions. Improved Pharma has always believed that investing time and energy in the advancement of pharmaceutical sciences helps everyone to succeed. Research efforts in 2019 focused on the use of subtractions and new software tools to isolate and identify intramolecular and intermolecular API domains in solid dispersions.

Looking forward to 2020, research will involve improving the detectability of amorphous domains in solid samples via a collaboration with Purdue University’s TEM facilities. Another key area of research will involve collaboration with Dr. Richard Weber, President of Materials Development Inc. in Evanston, IL. This research will continue exploring the many ways “lab on a drop” using acoustic levitation can accelerate development and reduce time to IND by performing screens in just one or two days with very small amounts of material. These research efforts support Improved Pharma’s long-range strategies that rely on the concepts of accelerated development and quality by design. By utilizing problem solving and analytical capabilities, it is possible to develop formulations and methods that both accelerate development and build quality into a system.

We wish all our clients the best for 2020 and do not hesitate to contact us if we can be of assistance.

About Improved Pharma

Improved Pharma is a research and information company dedicated to improving pharmaceutical methods, formulations, and processes. Dr. Stephen Byrn and Sarah Byrn founded the company in 2006 after the successful acquisition of their first company, SSCI. Dr. Pamela Smith joined the company in 2018 after an 18-year tenure with SSCI. Improved Pharma offers services such as analytical testing, synchrotron-based formulation design, and expert consulting aiding the development and defense of intellectual property matters.

Share article on social media or email: